what are the molecular events that fumonisin-induced porcine pulmonary
edema syndrome and equine leucoencephalomalacia have in common? Do th
ese animal diseases relate mechanistically to fumonisin toxicity in la
boratory rats? There is considerable data indicating that disruption o
f sphingolipid metabolism plays an important early role in all of thes
e diseases. In vitro studies have revealed that fumonisins and structu
rally related Alternaria alternata f. sp. lycopersici-toxin (AAL-toxin
) are potent inhibitors of the enzyme sphinganine (sphingosine) N-acyl
transferase (ceramide synthase). Soon after cultured cells or animals
are exposed to fumonisins there is a dramatic increase in the free sp
hingoid base, sphinganine, in tissues, serum and/or urine. Also, free
sphingosine concentration increases, complex sphingolipid concentratio
n decreases, and sphingoid base degradation products and other lipid p
roducts also increase. It is hypothesized that disruption of sphingoli
pid metabolism is an early molecular event in the onset and progressio
n of cell injury and the diseases associated with consumption of fumon
isins. However, the exact mechanisms responsible for the diseases will
not be easily revealed since the role of sphingolipids in cellular re
gulation is very complex and not yet fully understood. While fumonisin
B1 is non-genotoxic it is a complete carcinogen in rat liver. Recent
studies indicate that fumonisins inhibit hepatocyte proliferation in r
at liver. It has been hypothesized that hepatotoxicity and effects on
hepatocyte proliferation are critical determinants for fumonisin B1 ca
ncer initiation and promotion. Alternatively, recent studies have foun
d that fumonisin B-1 has mitogenic activity in cultured fibroblasts. I
t is conceivable that the mitogenic, cytostatic and cytotoxic potentia
l of fumonisin may all contribute to the animal diseases including liv
er cancer in rats.